You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》花旗下調輝瑞(PFE.US)目標價至42美元 評級「中性」
阿思達克 05-25 09:53
花旗發表研究報告指,近日中國每周錄得約6,500萬宗新冠確診個案,超出預期,但新一波染疫能否轉化為輝瑞(PFE.US)的收入來源仍為未知之數,強調今批染疫變異株主要為XBB,屬Omicron的變體,兩者具有相似的致病性。 該行指出,輝瑞新冠口服藥Paxlovid的NRDL緊急核准使用報銷已於2023年4月被撤銷,預期若住院率沒有大幅上升,不太可能會重新獲得緊急使用授權,因此雖然未來出現新變種可能性很高,但仍將今年Paxlovid預測下調,並將公司目標價從50美元降至42美元,評級為「中性」。(gc/k) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account